192 related articles for article (PubMed ID: 31621208)
1. The volume of
Wang SB; Liu JP; Lei KJ; Jia YM; Xu Y; Rong JF; Wang CX
Cancer Med; 2019 Dec; 8(17):7219-7226. PubMed ID: 31621208
[TBL] [Abstract][Full Text] [Related]
2. The absolute volume of PET-defined, active bone marrow spared predicts for high grade hematologic toxicity in cervical cancer patients undergoing chemoradiation.
Zhou YM; Freese C; Meier T; Go D; Khullar K; Sudhoff M; Lamba M; Kharofa J
Clin Transl Oncol; 2018 Jun; 20(6):713-718. PubMed ID: 29076030
[TBL] [Abstract][Full Text] [Related]
3. Dose-Volume Parameters of Spared Magnetic Resonance Imaging-Defined Active Bone Marrow Predict Hematologic Toxicity in Pelvic Malignancies Patients Undergoing Radiotherapy: A Cohort Study.
Gao T; Wei L; Jiang L; Ma S; Zhang W; Zhang Y; Wu F
Technol Cancer Res Treat; 2024; 23():15330338241255283. PubMed ID: 38752234
[No Abstract] [Full Text] [Related]
4. Single-photon emission computed tomography-defined active bone marrow-sparing volumetric-modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single-center prospective randomized controlled trial.
Wang S; Liu J; Lei K; Jia Y; Wang C; Zhang X; Li T
Cancer; 2023 Jul; 129(13):1995-2003. PubMed ID: 37043337
[TBL] [Abstract][Full Text] [Related]
5. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
[TBL] [Abstract][Full Text] [Related]
6. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
Wan J; Liu K; Li K; Li G; Zhang Z
Radiat Oncol; 2015 Aug; 10():162. PubMed ID: 26238572
[TBL] [Abstract][Full Text] [Related]
7. Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
Rose BS; Liang Y; Lau SK; Jensen LG; Yashar CM; Hoh CK; Mell LK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1185-91. PubMed ID: 22270171
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
[TBL] [Abstract][Full Text] [Related]
9. Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin.
Lewis S; Chopra S; Naga P; Pant S; Dandpani E; Bharadwaj N; Mahantshetty U; Engineer R; Swamidas J; Ghosh J; Gupta S; Shrivastava S
Br J Radiol; 2018 Dec; 91(1092):20180005. PubMed ID: 30179056
[TBL] [Abstract][Full Text] [Related]
10. Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.
Chang Y; Yang ZY; Li GL; Li Q; Yang Q; Fan JQ; Zhao YC; Song YQ; Wu G
Int J Gynecol Cancer; 2016 May; 26(4):770-6. PubMed ID: 26844613
[TBL] [Abstract][Full Text] [Related]
11. A Multi-atlas Approach for Active Bone Marrow Sparing Radiation Therapy: Implementation in the NRG-GY006 Trial.
Yusufaly T; Miller A; Medina-Palomo A; Williamson CW; Nguyen H; Lowenstein J; Leath CA; Xiao Y; Moore KL; Moxley KM; Chevere-Mourino CM; Eng TY; Zaid T; Mell LK
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1240-1247. PubMed ID: 32629079
[TBL] [Abstract][Full Text] [Related]
12. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
Huang J; Gu F; Ji T; Zhao J; Li G
Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
[TBL] [Abstract][Full Text] [Related]
13. Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer.
Kuncman Ł; Stawiski K; Masłowski M; Kucharz J; Fijuth J
Strahlenther Onkol; 2020 Nov; 196(11):998-1005. PubMed ID: 32621010
[TBL] [Abstract][Full Text] [Related]
14. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
[TBL] [Abstract][Full Text] [Related]
15. Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients.
Franco P; Arcadipane F; Ragona R; Lesca A; Gallio E; Mistrangelo M; Cassoni P; Arena V; Bustreo S; Faletti R; Rondi N; Morino M; Ricardi U
Med Oncol; 2016 Jul; 33(7):72. PubMed ID: 27277756
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy.
Noticewala SS; Li N; Williamson CW; Hoh CK; Shen H; McHale MT; Saenz CC; Einck J; Plaxe S; Vaida F; Yashar CM; Mell LK
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):797-805. PubMed ID: 28244416
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy.
Xiang X; Ding Z; Zeng Q; Feng L; Qiu C; Chen D; Lu J; Li N
Radiat Oncol; 2022 Mar; 17(1):48. PubMed ID: 35248087
[TBL] [Abstract][Full Text] [Related]
18. Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation.
Rose B; Mitra D; Hong TS; Jee KW; Niemierko A; Drapek LN; Blaszkowsky LS; Allen JN; Murphy JE; Clark JW; Ryan DP; Wo JY
Pract Radiat Oncol; 2017; 7(5):e291-e297. PubMed ID: 28462895
[TBL] [Abstract][Full Text] [Related]
19. Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation.
Rose BS; Jee KW; Niemierko A; Murphy JE; Blaszkowsky LS; Allen JN; Lee LK; Wang Y; Drapek LC; Hong TS; Wo JY
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):747-54. PubMed ID: 26972647
[TBL] [Abstract][Full Text] [Related]
20. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.
Klopp AH; Moughan J; Portelance L; Miller BE; Salehpour MR; Hildebrandt E; Nuanjing J; D'Souza D; Souhami L; Small W; Gaur R; Jhingran A
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):83-90. PubMed ID: 23582248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
